This study enrolled 32 adults, age 18–55, with peanut allergy in a 3:1 ratio to receive either an escalating dose of INT301 or placebo. Inclusion criteria included a positive SPT with a wheal diameter ...
ANAHEIM, Calif. (Nov. 9, 2023) – Oral immunotherapy for peanut allergy – introducing small amounts of peanut over a period of time to cause less of a reaction if the person eats something with peanut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results